evans blue has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Gao, S; Jacobson, O; Kiesewetter, DO; Lang, L; Liu, Y; Ma, Q; Ma, Y; Wang, G; Zhang, H; Zhu, L | 1 |
| Gonzalez, FJ; Kohan, DE; Nelson, RD; Yang, T; Zhang, A; Zhang, H | 1 |
2 other study(ies) available for evans blue and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.
Topics: Animals; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Stability; Evans Blue; Exenatide; Humans; Hypoglycemic Agents; Maleimides; Mice, Inbred C57BL; Naphthalenesulfonates; Peptides; Serum Albumin; Venoms | 2016 |
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Topics: Aldosterone; Animals; Biological Transport; Body Weight; Coloring Agents; Diabetes Mellitus, Type 2; Evans Blue; Gene Deletion; Genotype; Heterozygote; Hypoglycemic Agents; Immunohistochemistry; Integrases; Kidney; Kidney Tubules, Collecting; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nephrons; PPAR gamma; Promoter Regions, Genetic; Radioimmunoassay; Rosiglitazone; Sodium; Thiazolidinediones | 2005 |